


# PATENT COOPERATION TREATY



From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

Deshmukh, Jay R.  
RANBAXY LABORATORIES LIMITED  
600 College Road East  
Suite 2100  
Princeton, NJ 08540  
ETATS-UNIS D'AMERIQUE

## NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Rule 71.1)

Date of mailing  
(day/month/year) 19.07.2004

Applicant's or agent's file reference  
RLL-265WO

### IMPORTANT NOTIFICATION

International application No.  
PCT/IB 03/02166

International filing date (day/month/year)  
06.06.2003

Priority date (day/month/year)  
07.06.2002

Applicant  
RANBAXY LABORATORIES LIMITED et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international  
preliminary examining authority:



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized Officer

Ruiz Fernandez, J  
Tel. +49 89 2399-7960



# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Article 36 and Rule 70)

Applicant's or agent's file reference RLL-265WO	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/IB 03/02166	International filing date (day/month/year) 06.06.2003	Priority date (day/month/year) 07.06.2002
International Patent Classification (IPC) or both national classification and IPC A61K9/22		
Applicant RANBAXY LABORATORIES LIMITED et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  06.01.2004	Date of completion of this report  19.07.2004
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer  Hedegaard, A  Telephone No. +49 89 2399-8644  

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/IB 03/02166**

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, Pages**

1-17 as originally filed

**Claims, Numbers**

1-53 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  
☐ the language of publication of the international application (under Rule 48.3(b)).  
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.  
☐ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority in written form.  
☐ furnished subsequently to this Authority in computer readable form.  
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/IB 03/02166**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 49-53

because:

☒ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):

**see separate sheet**

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the Standard.

☐ the computer readable form has not been furnished or does not comply with the Standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	47,48
	No: Claims	1-46,49-53
Inventive step (IS)	Yes: Claims	
	No: Claims	1-53
Industrial applicability (IA)	Yes: Claims	1-48
	No: Claims	

2. Citations and explanations

**see separate sheet**

**Re Section III**

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. Claims 49-53 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

**Re Section V**

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Reference is made to the following documents:

D1: WO-A-0076478  
D2: WO-A-0059477  
D3: WO-A-0151033  
D4: EP-A-0 284 849  
D5: WO-A-03002151  
D6: WO-A-03035040

D1 discloses (see claim 1 and example 5) controlled release tablets comprising gabapentin and a rate-controlling polymer such as HPMC. A dissolution profile wherein after 5 hours no more than 80% of active ingredient is released is shown for a similar tablet comprising 5-aminosalicylic acid (example 1). The tablets are made by granulation of active ingredient in an inert matrix.

D2 discloses (see p. 5, l. 5-36; p. 7, l. 21; and p. 11, l. 19 - p. 12, l. 7) controlled release tablets comprising e.g. gabapentin and a rate-controlling polymer such as HPMC.

D3 discloses (see claims 1, 2 and 8) controlled release tablets comprising an active ingredient, e.g. gabapentin, and a matrix, e.g. a hydrophilic matrix, said tablets being obtained by granulation and compression.

2. Claims 1-3, 27-29 and 49 do not meet the requirements of Article 6 PCT in that

the matter for which protection is sought is not clearly defined. The claims attempt to define the subject-matter in terms of the result to be achieved (a certain release profile) which merely amounts to a statement of the underlying problem. The technical features necessary for achieving this result should be added.

3. The subject-matter of independent claims 1 and 49 is not novel (Art. 33(2) PCT) over D1-D3, each document taken separately (see above under item 1). As mentioned above under item 2 the feature "therapeutically effective plasma levels of gabapentin for a period of up to about 12 hours" is not suitable for making a clear distinction over the prior art.
4. The subject-matter of independent claim 27 is not novel over D3 (see above under item 1).
5. The subject-matter of independent claims 47 and 48 is novel since the exact process features have not been disclosed in the prior art documents.

The subject-matter of said claims differs from D1-D3 in specifying that the gabapentin is granulated with 5% to 80% by weight of HPMC/HPC having a certain viscosity. However, it is well known to the skilled person to granulate active ingredients with HPMC in order to obtain prolonged release of the therapeutic agent within a period of up to 12 hours. (see e.g. D4, p. 5, l. 19-35). Hence, the subject-matter of said claims does not appear to involve an inventive step (Art. 33(3) PCT).

6. A positive international preliminary report for the subject-matter of the dependent claims 2-26, 28-46 and 50-53 can only be established when they refer to independent claims which meet the requirements of the PCT.
7. For the assessment of the present claims 49-53 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/IB 03/02166

claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**8. Certain published documents (Rule 70.10)**

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date ( <i>valid claim</i> ) (day/month/year)
WO-A-03002151	09.01.2003	19.06.2002	26.06.2001
WO-A-03035040	01.05.2003	25.10.2002	25.10.2001

Although WO-A-03002151 (D5) and WO-A-03035040 (D6) do not constitute prior art within the meaning of Rule 64.1(b) PCT, they could become of relevance in the regional phase.

No check has been made as to whether the priorities have been validly claimed.